Biocept's EBIT per Share for the
three
months ended in Jun. 2023 was $-3.45.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-50.51.
During the past 3 years, the average EBIT per Share Growth Rate was 44.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 72.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Biocept's EBIT per Share or its related term are showing as below:
BIOCQ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 44.7 Med: 64.65 Max: 87.8
Current: 44.7
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Biocept was 87.80% per year. The lowest was 44.70% per year. And the median was 64.65% per year.
BIOCQ's 3-Year EBIT Growth Rate is ranked better than 91.53% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.7
vs BIOCQ: 44.70
Biocept's EBIT for the
three
months ended in Jun. 2023 was $-3.58 Mil.
Biocept EBIT per Share Historical Data
The historical data trend for Biocept's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocept (OTCPK:BIOCQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Biocept EBIT per Share Related Terms
Thank you for viewing the detailed overview of Biocept's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOCQ has been successfully added to your 